ArticleTranslational andrology and urology2022
Identification of a novel peripheral blood signature diagnosing subclinical acute rejection after renal transplantation.
Article in Translational andrology and urology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 4 citations in OpenAlex.
- Monitoring of Serological, Cellular and Genomic Biomarkers in Transplantation, Computational Prediction Models and Role of Cell-Free DNA in Transplant Outcome.International journal of molecular sciences · 2023Review
- Integrated analysis of cell-specific gene expression in peripheral blood using ISG15 as a marker of rejection in kidney transplantation.Frontiers in immunology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Subclinical acute rejection (subAR) can only be diagnosed by protocol biopsy and is correlated with worse graft outcomes. However, noninvasive biomarkers of subAR are lacked for kidney transplantation recipients in clinic. This study aims to utilize to construct a peripheral blood-based gene signature for subAR diagnosis after kidney transplantation. Methods: After systematically screening databases, two cohorts of high quality with 3-month blood profiles and biopsy-proven graft status from the Gene Expression Omnibus databases were employed as training and validation cohorts. Then, the support vector machine recursive feature elimination (SVM-RFE) and the least absolute shrinkage and selection operator (LASSO) logistic regression were used to identify key biomarkers for subAR. Subsequently, the stepwise logistic regression method was applied to construct a gene signature for subAR in the training cohort. Patients were divided into high-risk and low-risk groups based on the cutoff point identified by the receiver operating characteristic (ROC) curve. Then, the signature was validated in a validation cohort with fixed formula. The single-sample gene set enrichment analysis was used to estimate immune cells in the blood. Results: Fifty key biomarkers were filtered out with the machine learning algorithms. Then, a novel six-gene signature was constructed using the LASSO and stepwise logistic regression method. The signature had high accuracy in both training [area under the curve (AUC) =0.923] and validation cohort (AUC =0.855). Additionally, these six genes were found to have significant and consistent relationships with blood immune cells in both cohorts, especially for T cells subtypes. Conclusions: We developed and validated a novel noninvasive six-gene signature based on peripheral blood to diagnose subAR, which offered a potential tool for clinical practice. The six-gene signature offered a potential method to monitor patients following transplantation and make a timely intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.